Today’s edition features:
- Amryt Pharma (AMYT.L)
- Legendary Investments (LEG.L)
Visit Company News »
Wishing you a Merry Christmas and a Happy New Year!
Breakfast Today is taking a break for the festive period. Today’s issue is the last of 2017. We will be back again on Tuesday, 2nd January 2018. We wish all our readers a very Merry Christmas and a Prosperous New Year!
The FTSE-100 finished yesterday’s session 0.25% lower at 7,523.22, whilst the FTSE AIM All-Share index was up 0.07% at 1,022.49. In continental Europe, the CAC-40 finished 0.56% lower at 5,352.77 whilst the DAX was down 1.11% at 13,069.17.
Last night in New York, the Dow Jones closed 0.11% lower at 24,726.65, the S&P 500 fell 0.08% to end at 2,679.25 and the Nasdaq eased by 0.04% to 6,960.96.
In Asian markets this morning, the Nikkei 225 was down 0.12% at 22,864.28, while the Hang Seng was up 0.46% at 29,368.43.
In early trade today, WTI crude was 0.1% lower at $58.03 per barrel and Brent was down 0.17% at $64.45 per barrel.
Cost of global disasters ‘jumps to $306bn in 2017’
Disasters in 2017 caused losses of $306bn (£229bn), according to estimates from insurance giant Swiss Re. The figure represents a 63% jump from last year, and is well above the average of the past decade. The Americas was hardest hit, with hurricanes in the Caribbean and southern US, earthquakes in Mexico and wildfires in California. Despite the rise in the financial cost of disasters, there was no significant increase in the loss of lives. Swiss Re said more than 11,000 people died or went missing in disaster events in 2017, which is similar to 2016’s figure.
Source: BBC News
On Monday, 18th December 2017 Dr Dan Gooding, CEO of Nuformix answered questions posed by private investors at the Beaufort offices. Click here to see the interview.
Beaufort Securities acts as corporate broker to Nuformix plc
Amryt Pharma (AMYT.L, 20.00p) – Speculative Buy
Amryt Pharma yesterday announced that it has appointed Patrick Jordan as Vice-President of Global Distributor Markets. Mr. Jordan will support Amryt’s entry into the Kingdom of Saudi Arabia market, alongside its planned expansion into new territories in Central & Eastern Europe, Middle East, North Africa, and beyond. Mr. Jordan has worked in the pharmaceutical industry for the last 18 years including senior roles at Pfizer and Merck & Co (‘MSD’). At MSD, Mr. Jordan was the Managing Director of Saudi operations and Regional Managing Director of Eastern Europe and North Africa business. Amryt’s CEO, Dr. Joe Wiley, commented “[the appointment] reflects the progress we are making as we focus on our expanding opportunities across global markets”.
Our view: Lojuxta is approved for the treatment of Homozygous Familial Hypercholesterolaemia (‘HoFH’) and AP101 is currently in pivotal Phase 3 trials for the treatment for Epidermolysis Bullosa (‘EB’). Amryt has exclusive marketing rights for Lojuxta in the EEA, Middle East, North Africa, Turkey and Israel. Recently, Amryt announced that it signed an exclusive distributorship agreement for Lojuxta and AP101 in the Kingdom of Saudi Arabia with Faisal Musaed El Seif Saudi Pharmaceutical Company. This is a clear demonstration of global interest in Lojuxta along with AP101 as the latter moves closer to approval (interim analysis expected in H1 2018). The global market opportunity for EB is estimated to be over €1.3bn. Amryt’s successful raise of €15m gross in October 2018 along with its €10.9m existing cash (at 30 June 2017) and undrawn EIB debt facility of €10m are together more than sufficient to fund AP101’s Phase 3 clinical trials to completion. Beaufort’s valuation indicates Amryt is presently valued less than Lojuxta’s prudently discounted future cashflow (no value attributed to AP101 nor AP102!). Beaufort reiterates its Speculative Buy rating on the shares with target price of 65p.
Beaufort Securities provides corporate sponsored research to Amryt Pharma Plc
REQUEST A CALL FROM A BROKER REGARDING THIS RECOMMENDATION
Legendary Investments (LEG.L, 0.13p) – Speculative Buy
Legendary this morning announced that it has entered into an agreement to acquire 9.7% of Crowd for Angels (UK) Limited (‘CfA’), an owner-operator of the crowdfunding platform, ‘Crowd for Angels’, at a post money valuation for CfA of £3.7m. The 9.7% stake will be paid for through the issuance to CfA of 248,275,862 Legendary ordinary shares of 0.1 pence nominal value each which equates to 0.145p per Legendary Share (rank pari passu). The closing price on 19 December 2017 was 0.14p per Ordinary Share. Admission of new ordinary shares to AIM is scheduled to occur on or around 29 December 2017. Following admission, the company’s enlarged issued share capital will comprise of 3,292,912,755 ordinary shares with one voting right per share (no shares in treasury). Legendary’s Executive Chairman, Zafar Karim, commented “Legendary was the first outside investor in the successful tech company, Virtual Stock Holdings Limited. With its recent investment in IBS Corporation Limited, Legendary has a stake in a banking services platform and now, with the investment in Crowd for Angels, Legendary has a stake in a fintech platform. Technology, finance and its confluence, fintech are exciting sectors that will and are moulding the future”.
Our view: This is an encouraging move for Legendary. CfA was among the first crowdfunding platforms to be authorised by the FCA and approved by HMRC to manage the Innovative Finance ISA (IF-ISA). Since its launch in 2014, CfA has successfully completed 9 fundraisings and helped raise over £3m (both debt and equity) for investee companies. It is also the first crowd funding platform to be launching its own Liquid Crypto Bond with attached crypto tokens through an Initial Coin Offering (‘Liquid Crypto Bond’). With the imminent launch of its £50m Liquid Crypto Bond, CfA is in exciting phase of its development. For the year ended 30 June 2017, CfA had losses of £192,986. Simply valuing Legendary’s 7.2% Virtual Stock participation on the basis of Notion Capital’s recent funding injection, this on its own, provides a 20% or so premium to LEG’s current market capitalisation. In expectation of Legendary’s participation in VS becoming more realistically valued within LEG’s wider portfolio, Beaufort retains its Speculative Buy recommendation on the shares along with its 0.7p price target.
Beaufort Securities acts as corporate broker to Legendary Investments plc
REQUEST A CALL FROM A BROKER REGARDING THIS RECOMMENDATION
To read Beaufort’s full research archive click here
Charles Long, Ben Maitland, Sheldon Modeland & Kazunaga Senga
(t) +44 (0) 207 382 8384
Click here to see all next week’s planned corporate and economic announcements.
During the three months to end-November 2017, the number of stocks on which Beaufort Securities published recommendations was 237, and the recommendations were as follows: Buy – 37; Speculative Buy – 187; Hold – 11; Sell – 2.
Full definitions of the recommendations used by Beaufort Securities in its publications and their respective meanings can be found on our website here.
Important Risk Warnings and Disclaimers
This report is published by Beaufort Securities Ltd (“Beaufort Securities”). Beaufort Securities Ltd is Authorised and Regulated by the Financial Conduct Authority and is a Member of the London Stock Exchange.
RELIANCE ON THIS NOTE FOR THE PURPOSE OF ENGAGING IN ANY INVESTMENT ACTIVITY MAY EXPOSE YOU TO A SIGNIFICANT RISK OF LOSING ALL OF THE FUNDS, PROPERTY OR OTHER ASSETS INVESTED OR OF INCURRING ADDITIONAL LIABILITY.
This document is not an offer to buy or sell any security or currency. This document does not provide you with individually tailored investment advice. It has been prepared without regard to the your financial circumstances and objectives The appropriateness of a particular investment or currency will depend on your individual circumstances and objectives. The investments and shares referred to in this document may not be suitable for you.
This research is non-independent and is classified as a Marketing Communication under FCA rules. As such it has not been prepared in accordance with legal requirements designed to promote independence of investment research and it is not subject to the prohibition on dealing ahead of the dissemination of investment research in COBS 12.2.5. However Beaufort Securities has adopted internal procedures which prohibit analysts from dealing ahead of non-independent research, except for legitimate market making and fulfilling clients’ unsolicited orders.
By receiving this document, you will not be deemed a client or provided with the protections afforded to clients of Beaufort Securities. When distributing this document, Beaufort Securities is not acting for you and will not be responsible for providing advice to you in relation to this document. Accordingly, Beaufort Securities will not be responsible to you for providing the protections afforded to its clients.
Beaufort Securities may effect transactions in shares mentioned herein and may take proprietary trading positions in those shares, and may receive remuneration for the publication of its research and for other services. Beaufort Securities may be a shareholder in any of the companies mentioned in this report. Accordingly, this document may not be considered as objective or impartial. Additionally, information may be available to Beaufort Securities or the Group, which is not reflected in this material. The remuneration of the author of this report is not tied to the recommendations on any shares mentioned nor to the any transactions undertaken by Beaufort Securities or any affiliate company. Further information on Beaufort Securities’ policy regarding potential conflicts of interest in the context of investment research and Beaufort Securities’ policy on disclosure and conflicts in general are available on request. Please refer to http://www.beaufortsecurities.com/important-info.
Past performance is not a guarantee of future performance. Investments may go down in value as well as up and you may not get back the full amount invested. The listing requirements for securities listed on AIM or NEX are less demanding and trading in them may be less liquid than main markets. This may make it more difficult to buy and sell these securities.
This document includes certain statements, estimates, and projections with respect to the anticipated future performance of securities listed on stock exchanges and as to the market for these shares. Such statements, estimates, and projections are based on information that we consider reliable and may reflect various assumptions made concerning anticipated economic developments, which have not been independently verified and may or may not prove correct. No representation or warranty is made as to the accuracy of such statements, estimates, and projections or as to its fitness for the purpose intended and it should not be relied upon as such. Opinions expressed are our current opinions as of the date appearing on this material only and may change without notice. Other third parties may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views, and analytical methods of the analysts who prepared them. This report has not been disclosed to any of the companies mentioned herein prior to its publication.
This document is based on information Beaufort Securities has received from publicly available reports and industry sources. Beaufort Securities may not have verified all of this information with third parties. Neither Beaufort Securities nor its advisors, directors or employees can guarantee the accuracy, reasonableness or completeness of the information received from any sources consulted for this publication, and neither Beaufort Securities nor its advisors, directors or employees accepts any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by the applicable law). You should not rely on this document and should not use it substitution for the exercise of the independent judgment of yourself or your adviser.
The information contained in this document is confidential and is solely for use of those persons to whom it is addressed and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. Other persons who receive this document should not rely on it. Beaufort Securities, its directors, officers and employees may have positions in the securities mentioned herein.